BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 8604484)

  • 1. Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantation.
    Collins RH; Pineiro LA; Nemunaitis JJ; Jain VK; Waxman D; Miller WV; Fay JW
    Transfusion; 1995; 35(11):891-8. PubMed ID: 8604484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transfusion of donor peripheral blood buffy coat cells as effective treatment for relapsed acute leukemia after transplantation of allogeneic bone marrow or peripheral blood stem cells from the same donor.
    Tzeng CH; Lin JS; Lee JC; Yung CH; Hu HY; Chen PM
    Transfusion; 1996 Aug; 36(8):685-90. PubMed ID: 8780662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.
    Verdonck LF; Petersen EJ; Lokhorst HM; Nieuwenhuis HK; Dekker AW; Tilanus MG; de Weger RA
    Bone Marrow Transplant; 1998 Dec; 22(11):1057-63. PubMed ID: 9877267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Successful treatment of recurrent chronic myelogenous leukemia in allogeneic marrow transplant recipient with the donor leukocyte transfusion, without induction of acute graft-versus-host disease].
    Yamazaki H; Nakao S; Takamatsu H; Ito T; Ueda M; Shiobara S; Matsuda T
    Rinsho Ketsueki; 1995 Jul; 36(7):677-81. PubMed ID: 7563596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-alpha and donor buffy coat transfusions for treatment of relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Hertenstein B; Wiesneth M; Novotny J; Bunjes D; Stefanic M; Heinze B; Hübner G; Heimpel H; Arnold R
    Transplantation; 1993 Nov; 56(5):1114-8. PubMed ID: 8249110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activated allogeneic cell therapy (allo-ACT) for relapsed chronic myelogenous leukemia (CML) refractory to buffy coat transfusions post-allogeneic bone marrow transplantation.
    Kapelushnik J; Nagler A; Or R; Naparstek E; Ackerstein A; Samuel S; Morecki S; Nabet C; Slavin S
    Bone Marrow Transplant; 1996 Dec; 18(6):1153-6. PubMed ID: 8971387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S; Nakao S; Ueda M; Yamazaki H; Takahashi S; Asano S; Yabe H; Kato S; Imoto S; Maruta A; Yoshida T; Gondo H; Morishima Y; Kodera Y
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unrelated donor leukocyte infusions to treat relapse after unrelated donor bone marrow transplantation.
    Leis J; Porter DL
    Leuk Lymphoma; 2002 Jan; 43(1):9-17. PubMed ID: 11908741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor buffy coat infusions for a patient with myelodysplastic syndrome who relapsed following allogeneic bone marrow transplantation.
    Tsuzuki M; Maruyama F; Kojima H; Ezaki K; Hirano M
    Bone Marrow Transplant; 1995 Sep; 16(3):487-9. PubMed ID: 8535326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
    Collins RH; Shpilberg O; Drobyski WR; Porter DL; Giralt S; Champlin R; Goodman SA; Wolff SN; Hu W; Verfaillie C; List A; Dalton W; Ognoskie N; Chetrit A; Antin JH; Nemunaitis J
    J Clin Oncol; 1997 Feb; 15(2):433-44. PubMed ID: 9053463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation.
    Giralt S; Escudier S; Kantarjian H; Deisseroth A; Freireich EJ; Andersson BS; O'Brien S; Andreeff M; Fisher H; Cork A
    N Engl J Med; 1993 Sep; 329(11):757-61. PubMed ID: 7688862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-CSF-mobilized donor leukocyte infusions as immunotherapy in acute leukemia relapsing after allogeneic marrow transplantation.
    Mandanas RA; Saez RA; Selby GB; Confer DL
    J Hematother; 1998 Oct; 7(5):449-56. PubMed ID: 9829319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of mixed chimerism and immune modulation on GVHD, disease recurrence and survival after HLA-identical marrow transplantation for hematologic malignancies.
    Park SJ; Min WS; Yang IH; Kim HJ; Min CK; Eom HS; Kim DW; Han CW; Lee JW; Kim CC
    Korean J Intern Med; 2000 Dec; 15(3):224-31. PubMed ID: 11242811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Unrelated Allogeneic Bone Marrow Transplantation Facilitated by the Japan Marrow Donor Program.
    Miyamoto T; Fukuda T; Nakashima M; Henzan T; Kusakabe S; Kobayashi N; Sugita J; Mori T; Kurokawa M; Mori SI
    Biol Blood Marrow Transplant; 2017 Jun; 23(6):938-944. PubMed ID: 28219836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
    Kolb HJ; Mittermüller J; Clemm C; Holler E; Ledderose G; Brehm G; Heim M; Wilmanns W
    Blood; 1990 Dec; 76(12):2462-5. PubMed ID: 2265242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic bone marrow transplantation in the treatment of hematologic diseases.
    Yee GC; McGuire TR
    Clin Pharm; 1985; 4(2):149-60. PubMed ID: 3886273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.